Literature DB >> 10973301

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.

T Hanke1, A J McMichael.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10973301     DOI： 10.1038/79626

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  47 in total

1.  Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.

Authors:  C Fayolle; A Osickova; R Osicka; T Henry; M J Rojas; M F Saron; P Sebo; C Leclerc
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  Nonviral DNA vectors for immunization and therapy: design and methods for their obtention.

Authors:  Ernesto G Rodríguez
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

Review 3.  T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Authors:  Bette T Korber; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

4.  Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys.

Authors:  Kathryn E Stephenson; Adam SanMiguel; Nathaniel L Simmons; Kaitlin Smith; Mark G Lewis; James J Szinger; Bette Korber; Dan H Barouch
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

Review 5.  New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials.

Authors:  Gaëlle Vandermeulen; Corinne Marie; Daniel Scherman; Véronique Préat
Journal:  Mol Ther       Date:  2011-08-30       Impact factor: 11.454

6.  Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.

Authors:  Maximillian Rosario; John Fulkerson; Shamit Soneji; Joe Parker; Eung-Jun Im; Nicola Borthwick; Anne Bridgeman; Charles Bourne; Joan Joseph; Jerald C Sadoff; Tomás Hanke
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

7.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

Authors:  Hanne Gahéry-Ségard; Gilles Pialoux; Suzanne Figueiredo; Céline Igéa; Mathieu Surenaud; Jessintha Gaston; Helene Gras-Masse; Jean-Paul Lévy; Jean-Gérard Guillet
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Authors:  Mark J Geels; Sheri A Dubey; Kiersten Anderson; Elly Baan; Margreet Bakker; Georgios Pollakis; William A Paxton; John W Shiver; Jaap Goudsmit
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.